Fundraising FoxSpotlight Therapeutics
San Francisco, US · Founded 2017 · Delaware corporation · 6 known investors
Find your way into Spotlight Therapeutics
Sign up to find every way you can get introduced to Spotlight Therapeutics
- Your email: who you already know at Spotlight Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Spotlight Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Founders & leadership
Board
Investors · 6
How we know: Team Builder Ventures's portfolio page · Not right? Tell us
How we know: board seat on SEC Form D · biospace.com · funding news · Not right? Tell us
How we know: biospace.com · funding news · Not right? Tell us
Also in the syndicate · 3
Reported raises · per SEC filings
Form D private placements$61.6M disclosed across 4 rounds · 2017–2021
▶$32.2MraisedJan 2022 · 11 investors · BiotechnologyRule 506(b)
- Mary Haak-FrendschoExecutive Officer
- Jacob CornDirector
- Alexander MarsonDirector
- Krishna YeshwantDirector
- Patrick David HsuDirector
- Offering amount
- $65M
- Amount sold
- $32.2M
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$15.2MraisedMar 2021 · 15 investors · BiotechnologyRule 506(b)
- Mary Haak-FrendschoExecutive Officer, Director
- Jacob CornDirector
- Alexander MarsonDirector
- Blake ByersDirector
- Patrick David HsuDirector
- Offering amount
- $16M
- Amount sold
- $15.2M
- First sale
- Sep 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$6.9MraisedSep 2019 · 6 investors · Other Health CareRule 506(b)
- Blake ByersDirector
- Jacob CornDirector
- Patrick David HsuDirector
- Alexander MarsonDirector
- Mary HaakFrendschoExecutive Officer, Director
- Offering amount
- $7.1M
- Amount sold
- $6.9M
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$7.3MraisedJan 2018 · 5 investors · Other Health CareRule 506(b)
- ALEXANDER MARSONExecutive Officer, Director
- PATRICK DAVID HSUDirector
- BLAKE BYERSDirector
- JACOB CORNDirector
- Offering amount
- $12M
- Amount sold
- $7.3M
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- Who are Spotlight Therapeutics's investors?
- Spotlight Therapeutics's investors include Team Builder Ventures, GV (Google Ventures), Magnetic Ventures.
- How much funding has Spotlight Therapeutics raised?
- Spotlight Therapeutics has disclosed $61.6M raised across 4 rounds.
- Where is Spotlight Therapeutics headquartered?
- Spotlight Therapeutics is headquartered in San Francisco, US.